Search company, investor...

Full Genomes

fullgenomes.com

Total Raised

$610K

Funding, Valuation & Revenue

6 Fundings

Full Genomes's latest funding round was a Unattributed - VI for $0.02M on May 9, 2016.

Full Genomes's 2015 revenue was <$1M. Full Genomes's most recent revenue is from 2014.

Sign up for a free trial to see revenue data from 2015, 2014 and more.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

5/9/2016

Unattributed - VI

$0.02M

Undisclosed Investors

$0.00B

((9.99x))

FY 1234

1

10/26/2015

Unattributed - V

$99M

<$1M

FY 2015

10

9/14/2015

Unattributed - IV

$99M

$0.00B

((9.99x))

FY 1234

10

12/9/2014

Unattributed - III

$99M

$0.00B

((9.99x))

FY 1234

10

12/9/2014

Unattributed - II

$99M

$0.00B

((9.99x))

FY 1234

10

Date

5/9/2016

10/26/2015

9/14/2015

12/9/2014

12/9/2014

Round

Unattributed - VI

Unattributed - V

Unattributed - IV

Unattributed - III

Unattributed - II

Amount

$0.02M

$99M

$99M

$99M

$99M

Investors

Undisclosed Investors

Valuation

Revenue

$0.00B

((9.99x))

FY 1234

<$1M

FY 2015

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

Sources

1

10

10

10

10

This profile has not been claimed.

You're more than your latest funding, tell our customers your company's story.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.